PMID- 11932897
OWN - NLM
STAT- MEDLINE
DCOM- 20020429
LR  - 20190620
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 94
IP  - 7
DP  - 2002 Apr 1
TI  - Expression and prognostic significance of PTEN product protein in patients with 
      esophageal squamous cell carcinoma.
PG  - 1955-60
AB  - BACKGROUND: PTEN is a candidate tumor-suppressor gene in a variety of malignant 
      tumors. The prognostic importance of PTEN product protein (PTEN) and its 
      correlation with clinicopathologic characteristics have yet to be delineated in 
      patients with esophageal carcinoma. METHODS: Specimens from 97 patients with 
      esophageal squamous cell carcinoma were used for the immunohistochemical 
      evaluation of PTEN expression. RESULTS: PTEN expression was detected in the 
      nucleus in 48 specimens (49.5%). There were statistically significant 
      correlations between nuclear PTEN expression and macroscopic tumor 
      classification, T stage, and American Joint Committee on Cancer (AJCC) stage (P < 
      0.01), indicating that PTEN expression was down-regulated by advancement of the 
      disease process. There were no statistically significant correlations between 
      nuclear PTEN expression and the intensity and extent of cytoplasmic PTEN 
      expression. The 10-year overall survival rate was significantly better in 
      patients with positive nuclear PTEN expression (n = 48 patients) compared with 
      the rate in patients with negative nuclear PTEN expression (n = 49 patients; P < 
      0.01). The results of a multivariate analysis of factors that were prognostic for 
      survival showed that AJCC stage (P < 0.05; relative risk, 2.038) and negative 
      nuclear PTEN expression (P < 0.05; relative risk, 1.825) were significant factors 
      indicative of poor survival. CONCLUSIONS: Nuclear PTEN expression may be a 
      favorable biologic marker and a useful prognostic indicator in patients with 
      esophageal squamous cell carcinoma.
CI  - Copyright 2002 American Cancer Society.
FAU - Tachibana, Mitsuo
AU  - Tachibana M
AD  - Second Department of Surgery, Shimane Medical University, Enya-cho 89-1, Izumo 
      693-8501, Shimane, Japan.
FAU - Shibakita, Muneaki
AU  - Shibakita M
FAU - Ohno, Satoshi
AU  - Ohno S
FAU - Kinugasa, Shoichi
AU  - Kinugasa S
FAU - Yoshimura, Hiroshi
AU  - Yoshimura H
FAU - Ueda, Shuhei
AU  - Ueda S
FAU - Fujii, Toshiyuki
AU  - Fujii T
FAU - Rahman, Mohammad A
AU  - Rahman MA
FAU - Dhar, Dipok K
AU  - Dhar DK
FAU - Nagasue, Naofumi
AU  - Nagasue N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 3.1.3.2 (Phosphoric Monoester Hydrolases)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma, Squamous Cell/*metabolism/mortality/pathology
MH  - Cell Nucleus/metabolism
MH  - Cytoplasm/metabolism
MH  - Esophageal Neoplasms/*metabolism/mortality/pathology
MH  - Female
MH  - *Genes, Tumor Suppressor
MH  - Germ-Line Mutation
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - PTEN Phosphohydrolase
MH  - Phosphoric Monoester Hydrolases/*metabolism
MH  - Prognosis
MH  - Survival Rate
MH  - Tumor Suppressor Proteins/*metabolism
EDAT- 2002/04/05 10:00
MHDA- 2002/05/01 10:01
CRDT- 2002/04/05 10:00
PHST- 2002/04/05 10:00 [pubmed]
PHST- 2002/05/01 10:01 [medline]
PHST- 2002/04/05 10:00 [entrez]
AID - 10.1002/cncr.10410 [pii]
AID - 10.1002/cncr.0678 [doi]
PST - ppublish
SO  - Cancer. 2002 Apr 1;94(7):1955-60. doi: 10.1002/cncr.0678.